ramucirumab Injection

Brand(s)
Cyramza
Category(s)
prescription
SPL Type(s)
Human Prescription
Master SPL
Eli Lilly And Company (2015-05-29)
Oldest Current Product
2014-04-21
License(s)
BLA
RxNORM
INJECTION\RAMUCIRUMAB
SPL Active
INTRAVENOUS\SOLUTION\RAMUCIRUMAB
SPL Moiety
INTRAVENOUS\SOLUTION\RAMUCIRUMAB

product(s) by strength(s)

10 ml ramucirumab 10 mg/ml injection

original product(s)(s)

#idbrandcategorylabelerfirst marketedactive ingredient(s)routedose formapplicationspl
1000027669CyramzaBLAEli Lilly And Company2014-04-21RAMUCIRUMABINTRAVENOUSSOLUTION125477c6080942-dee6-423e-b688-1272c2ae90d4

50 ml ramucirumab 10 mg/ml injection

original product(s)(s)

#idbrandcategorylabelerfirst marketedactive ingredient(s)routedose formapplicationspl
1000027678CyramzaBLAEli Lilly And Company2014-04-21RAMUCIRUMABINTRAVENOUSSOLUTION125477c6080942-dee6-423e-b688-1272c2ae90d4

application(s)

#idtitleapprovedtradenamesfda division
1125477ramucirumab Application2014-04-21CyramzaCDER

spl(s)

#idtitlecategorytypelabelerlast updateversionproduct(s)
1c6080942-dee6-423e-b688-1272c2ae90d4 (view SPL)These highlights do not include all the information needed to use CYRAMZA safely and effectively. See full prescribing information for CYRAMZA.CYRAMZA (ramucirumab) injection, for intravenous useInitial U.S. Approval: 2014prescriptionHuman PrescriptionEli Lilly And Company2015-05-2913000027669, 000027678

Data from: FDAOB, FDAPB, LOINC, MTHSPL, NDFRT, NCIT, RxNORM, UNII